Pfizer to scale down early-stage rare disease research

US pharma large Pfizer Inc. stated on Thursday it’s planning to realign its early-stage research into remedies for rare illnesses and oncology, to give attention to areas like rare and benign hematology.

Pfizer may even transfer away from having a rare disease research unit to align essential rare disease packages to areas throughout its research items.

“We are refocusing our approach to early discovery and development research in rare disease and oncology,” a spokesperson stated in an announcement to Reuters, including that the corporate will discover externalization alternatives for “a number of highly innovative, niche programs.”

Pfizer stated its oncology research portfolio will change into much more centered round breast, prostate and hematological most cancers franchises.

Monetary newspaper Barron’s first reported the information on Thursday. – Reuters

Source link